Every compound, graded against the record.
Per-compound reviews that grade efficacy and harm separately by the strength of the human evidence — cited to primary sources, and honest about how thin that evidence often is.
Compound reviews
6 compounds on record. Each review states drug class, mechanism, graded efficacy and safety, the human trials on record, legal status, and references.
Ostarine (MK-2866 / Enobosarm)
The prototypical, most clinically studied SARM — an oral nonsteroidal androgen-receptor agonist that reliably adds lean body mass in trials but has never won FDA approval, failed its pivotal muscle-function endpoint, and carries real liver, lipid and hormonal harm signals.
RAD-140 (Testolone)
A potent investigational nonsteroidal SARM — now advanced as the oncology drug "vosilasarm" — that is widely sold illegally for muscle-building and has caused multiple documented cases of severe drug-induced liver injury; the only human efficacy data are in breast cancer, not bodybuilding.
LGD-4033 (Ligandrol)
A nonsteroidal, orally active SARM that reliably increases lean body mass in short human trials, but suppresses testosterone and has caused cholestatic liver injury; it is not approved for any medical use anywhere.
Cardarine (GW-501516)
A discontinued GSK/Ligand PPARδ agonist — not a SARM — that GlaxoSmithKline abandoned after two-year rodent bioassays showed it caused cancer in multiple organs; it has never been approved for human use and is banned in sport at all times.
MK-677 (Ibutamoren)
An oral ghrelin-receptor agonist that reliably raises GH and IGF-1 to young-adult levels, but repeatedly failed to deliver clinical benefit in trials and carries a congestive-heart-failure safety signal — and it is not a SARM.
YK-11
A steroid-derived compound sold as a "SARM" and myostatin inhibitor, with no human trials — its entire evidence base is cell-culture and animal work.